Status:
RECRUITING
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
Lead Sponsor:
Reistone Biopharma Company Limited
Conditions:
Atopic Dermatitis of Adults
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis
Eligibility Criteria
Inclusion
- Age ≥18 years old and ≤75 years old at screening.
- History of atopic dermatitis ≥ 6 months.
- BSA is between 3% and 20% (inclusive) and EASI score is ≥ 5 and vIGA-AD is 2 or 3.
- The subjects signed informed consent before any study-related procedures began.
Exclusion
- Diagnosis of other dermatologic diseases at screening.
- Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study.
- Subjects with any other persistent active autoimmune disease.
- Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline.
Key Trial Info
Start Date :
September 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT07158151
Start Date
September 25 2025
End Date
May 1 2026
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510091